Moderna (MRNA)
International Stocks
Sell
The speaker examines FDA vaccine approval processes and recent regulatory decisions regarding company products.
Scott Gottlieb
CNBC Television
Loading...
Loading...
Coverage, strength, recency, conviction and momentum.
Covered by 5 analysts
Significant disagreement among analysts
Last evaluation 63+ days ago - stale data
Both buy and sell recommendations exist
Decreasing interest recently
Newest calls at the top.
The speaker examines FDA vaccine approval processes and recent regulatory decisions regarding company products.
The speaker analyzes mRNA-based flu vaccine applications and the FDA review process within the framework of clinical data standards.
The company's financial results and uncertainties in regulatory processes with the FDA are discussed.
Dr. Mani Foroohar evaluates Moderna's recent stock rally driven by cancer vaccine data, while scrutinizing the baseline characteristics of the study which he deems potentially misleading. He also assesses the management's decision to reduce investment in late-stage vaccine trials and the potential impact of the upcoming IP dispute in March.
The speaker discusses the 5-year data obtained from the company's cancer vaccine studies and the stock's transition away from being COVID-focused.
The speaker discusses the biotechnology company's updated 2025 revenue targets and expectations for improvements in operating expenses.
The speaker scrutinizes the positive pricing in the stock, developments in the cancer vaccine field, and potential medical breakthroughs.
The speaker discusses the development process of Moderna's mRNA technology and the impact of publicly funded research on the company's strategic direction.
The host evaluates the impact of FDA officials' statements regarding vaccine restrictions and safety concerns on the stock.
The speaker examines FDA vaccine approval processes and recent regulatory decisions regarding company products.
The speaker analyzes mRNA-based flu vaccine applications and the FDA review process within the framework of clinical data standards.
The company's financial results and uncertainties in regulatory processes with the FDA are discussed.
Dr. Mani Foroohar evaluates Moderna's recent stock rally driven by cancer vaccine data, while scrutinizing the baseline characteristics of the study which he deems potentially misleading. He also assesses the management's decision to reduce investment in late-stage vaccine trials and the potential impact of the upcoming IP dispute in March.
The speaker discusses the 5-year data obtained from the company's cancer vaccine studies and the stock's transition away from being COVID-focused.
The speaker discusses the biotechnology company's updated 2025 revenue targets and expectations for improvements in operating expenses.